Markus Ketteler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Markus Ketteler has a total of 315 co-authors. Here are the top co-authors by number of shared publications:
Patrick H. Biggar
A Division of Nephrology , Klinikum Coburg GmbH , Coburg , Germany
9 shared publications- Jürgen Floege
Department of Nephrology and Clinical Immunology, University Hospital, Rheinisch Westfälische Technische Hochschule Aachen, Aachen, Germany
5 shared publications - Patrick Biggar
Department of Nephrology, Klinikum Coburg, GmbH, Coburg, Germany
4 shared publications Amit Sharma
Nephrian, Thousand Oaks, CA, USA
3 shared publicationsJürgen Floege
RWTH University Hospital Aachen, Aachen, Germany
3 shared publicationsKevin J. Martin
3 shared publications
Latest Publications
- 18 December 2018
- Published by Georg Thieme Verlag KG in Dialyse aktuell
- Vol. 22 (S 01) , S4-S8
Chronisches Nierenversagen – Update 2018
Zusammenfassung: Die CANVAS-Programm-Studie hat mit Canagliflozin die Nephroprotektion, welche mit Empagliflozin publiziert wurde (EMPA-REG-Outcome-Studie), bestätigt. Die Therapie mit Liraglutide in der LEADER-Studie suggeriert Nephroprotektion über eine Reduktion der Albuminurie und geringerem eGFR-Abfall (eGFR: geschätzte glomeruläre Filtrationsrate) in Subgruppen/Stadien der diabetischen Nierenerkrankung. Im Juli 2017 erfolgte ein Update der KDIGO (Kidney Disease: Improving Global Outcomes) -2009-Leitlinie zur Diagnostik und Therapie der Störungen des Mineral- und Knochenhaushalts bei chronischen Nierenerkrankungen. Änderungen betrafen die Knochendichtemessung, die Therapie von Hyperphosphatämie und Hyperparathyreoidismus im Prädialysestadium und eine Warnung vor exzessiver Kalziumexposition. Ein neues parenterales Kalzimimetikum Zwei Phase-III-Studien zum Einsatz eines neuen parenteralen Kalzimimetikums (Etelcalcitid) wurden publiziert.
- 18 December 2018
- Published by Georg Thieme Verlag KG in Dialyse aktuell
- Vol. 22 (S 01) , S4-S8
Chronisches Nierenversagen – Update 2018
Zusammenfassung: Die CANVAS-Programm-Studie hat mit Canagliflozin die Nephroprotektion, welche mit Empagliflozin publiziert wurde (EMPA-REG-Outcome-Studie), bestätigt. Die Therapie mit Liraglutide in der LEADER-Studie suggeriert Nephroprotektion über eine Reduktion der Albuminurie und geringerem eGFR-Abfall (eGFR: geschätzte glomeruläre Filtrationsrate) in Subgruppen/Stadien der diabetischen Nierenerkrankung. Im Juli 2017 erfolgte ein Update der KDIGO (Kidney Disease: Improving Global Outcomes) -2009-Leitlinie zur Diagnostik und Therapie der Störungen des Mineral- und Knochenhaushalts bei chronischen Nierenerkrankungen. Änderungen betrafen die Knochendichtemessung, die Therapie von Hyperphosphatämie und Hyperparathyreoidismus im Prädialysestadium und eine Warnung vor exzessiver Kalziumexposition. Ein neues parenterales Kalzimimetikum Zwei Phase-III-Studien zum Einsatz eines neuen parenteralen Kalzimimetikums (Etelcalcitid) wurden publiziert.
- Open Access
- 29 May 2018
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 34 (7) , 1163-1170
Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease–mineral bone disorder parameters in dialysis patients
Treatment of hyperphosphataemia is the primary goal of chronic kidney disease–mineral and bone disorder (CKD-MBD) management. This post hoc analysis of a randomized, Phase 3 study evaluated the effects of 1-year treatment with the phosphate binders sucroferric oxyhydroxide or sevelamer carbonate (‘sevelamer’) on CKD-MBD indices among dialysis patients with hyperphosphataemia. After a 2- to 4-week washout from previous phosphate binders, 1059 patients were randomized 2:1 to sucroferric oxyhydroxide 1.0–3.0 g/day (n = 710) or sevelamer 2.4–14.4 g/day (n = 349) for up to 24 weeks. Eligible patients enrolled in a 28-week extension. This post hoc analysis was performed for patients who completed ≥1 year of continuous treatment (n = 549). As the treatment groups showed similar CKD-MBD outcomes, the data were pooled for this analysis. Phosphate-binder therapy was associated with significant and sustained 30% reductions in serum phosphorus (P < 0.001). Median intact fibroblast growth factor-23 (FGF-23) also significantly decreased (P < 0.001) by 64% over 1 year. Intact parathyroid hormone decreased significantly after 24 weeks (P < 0.001), but levels returned to near baseline values by Week 52; minimal changes in serum calcium were observed. Of the bone resorption markers evaluated, tartrate-resistant acid phosphatase 5b (TRAP5b) decreased significantly (P < 0.001), whereas CTx increased transiently but returned to baseline levels by Week 52. The bone formation markers bone-specific alkaline phosphatase and osteocalcin both increased over 1 year of treatment. Overall, 1 year of sucroferric oxyhydroxide or sevelamer treatment significantly reduced serum FGF-23, which has been associated with clinical benefit in patients with CKD. The trend towards increased bone formation marker levels indicates a beneficial effect on bone metabolism.
- 29 May 2018
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 34 (7) , 1163-1170
Open AccessEffects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease–mineral bone disorder parameters in dialysis patients
Treatment of hyperphosphataemia is the primary goal of chronic kidney disease–mineral and bone disorder (CKD-MBD) management. This post hoc analysis of a randomized, Phase 3 study evaluated the effects of 1-year treatment with the phosphate binders sucroferric oxyhydroxide or sevelamer carbonate (‘sevelamer’) on CKD-MBD indices among dialysis patients with hyperphosphataemia. After a 2- to 4-week washout from previous phosphate binders, 1059 patients were randomized 2:1 to sucroferric oxyhydroxide 1.0–3.0 g/day (n = 710) or sevelamer 2.4–14.4 g/day (n = 349) for up to 24 weeks. Eligible patients enrolled in a 28-week extension. This post hoc analysis was performed for patients who completed ≥1 year of continuous treatment (n = 549). As the treatment groups showed similar CKD-MBD outcomes, the data were pooled for this analysis. Phosphate-binder therapy was associated with significant and sustained 30% reductions in serum phosphorus (P < 0.001). Median intact fibroblast growth factor-23 (FGF-23) also significantly decreased (P < 0.001) by 64% over 1 year. Intact parathyroid hormone decreased significantly after 24 weeks (P < 0.001), but levels returned to near baseline values by Week 52; minimal changes in serum calcium were observed. Of the bone resorption markers evaluated, tartrate-resistant acid phosphatase 5b (TRAP5b) decreased significantly (P < 0.001), whereas CTx increased transiently but returned to baseline levels by Week 52. The bone formation markers bone-specific alkaline phosphatase and osteocalcin both increased over 1 year of treatment. Overall, 1 year of sucroferric oxyhydroxide or sevelamer treatment significantly reduced serum FGF-23, which has been associated with clinical benefit in patients with CKD. The trend towards increased bone formation marker levels indicates a beneficial effect on bone metabolism.
- Open Access
- 1 May 2018
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 33 (suppl_1) , i242
FP593REAL-WORLD SAFETY AND EFFECTIVENESS OF SUCROFERRIC OXYHYDROXIDE IN DIALYSIS PATIENTS: AN INTERIM ANALYSIS OF THE VERIFIE STUDY
INTRODUCTION AND AIMS: Sucroferric oxyhydroxide (SFOH) is a non-calcium-, iron-based phosphate binder (PB) indicated for the treatment of hyperphosphataemia in dialysis patients. The VERIFIE (Velphoro Evaluation of Real-lIfe saFety, effectIveness and adherencE) study is evaluating the safety and effectiveness of SFOH in dialysis patients in routine clinical practice.
- 1 May 2018
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 33 (suppl_1) , i242
Open AccessFP593REAL-WORLD SAFETY AND EFFECTIVENESS OF SUCROFERRIC OXYHYDROXIDE IN DIALYSIS PATIENTS: AN INTERIM ANALYSIS OF THE VERIFIE STUDY
INTRODUCTION AND AIMS: Sucroferric oxyhydroxide (SFOH) is a non-calcium-, iron-based phosphate binder (PB) indicated for the treatment of hyperphosphataemia in dialysis patients. The VERIFIE (Velphoro Evaluation of Real-lIfe saFety, effectIveness and adherencE) study is evaluating the safety and effectiveness of SFOH in dialysis patients in routine clinical practice.
- 1 May 2018
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 33 (suppl_1) , i37-i38
FO047REAL-WORLD EFFECTIVENESS OF SUCROFERRIC OXYHYDROXIDE FOR SERUM PHOSPHORUS CONTROL IN DIALYSIS PATIENTS: AN INTERIM SUBGROUP ANALYSIS OF THE VERIFIE STUDY
INTRODUCTION AND AIMS: Sucroferric oxyhydroxide (SFOH) is an iron-based phosphate binder (PB) indicated for the treatment of hyperphosphataemia in CKD patients undergoing dialysis. This analysis of the VERIFIE study evaluated the real-world effectiveness of SFOH for the control of serum phosphorus (sP) levels in different subgroups of study patients.
- 1 May 2018
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 33 (suppl_1) , i37-i38
FO047REAL-WORLD EFFECTIVENESS OF SUCROFERRIC OXYHYDROXIDE FOR SERUM PHOSPHORUS CONTROL IN DIALYSIS PATIENTS: AN INTERIM SUBGROUP ANALYSIS OF THE VERIFIE STUDY
INTRODUCTION AND AIMS: Sucroferric oxyhydroxide (SFOH) is an iron-based phosphate binder (PB) indicated for the treatment of hyperphosphataemia in CKD patients undergoing dialysis. This analysis of the VERIFIE study evaluated the real-world effectiveness of SFOH for the control of serum phosphorus (sP) levels in different subgroups of study patients.
- Top Cited Papers
- 20 March 2018
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 168 (6) , 422-430
Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder: Synopsis of the Kidney Disease: Improving Global Outcomes 2017 Clinical Practice Guideline Update
The Kidney Disease: Improving Global Outcomes (KDIGO) 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD–MBD) is a selective update of the prior CKD–MBD guideline published in 2009. The guideline update and the original publication are intended to assist practitioners caring for adults with CKD and those receiving long-term dialysis. Development of the guideline update followed an explicit process of evidence review and appraisal. The approach adopted by the Work Group and the evidence review team was based on systematic reviews of relevant trials, appraisal of the quality of the evidence, and rating of the strength of recommendations according to the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach. Searches of the English-language literature were conducted through September 2015 and were supplemented with targeted searches through February 2017. Final modification of the guidelines was informed by a public review process involving numerous stakeholders, including patients, subject matter experts, and industry and national organizations. The update process resulted in the revision of 15 recommendations. This synopsis focuses primarily on recommendations for diagnosis of and testing for CKD–MBD and treatment of CKD–MBD that emphasizes decreasing phosphate levels, maintaining calcium levels, and addressing elevated parathyroid hormone levels in adults with CKD stage G3a to G5 and those receiving dialysis. Key elements include basing treatment on trends in laboratory values rather than a single abnormal result and being cautious to avoid hypercalcemia when treating secondary hyperparathyroidism.
- 20 March 2018
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 168 (6) , 422-430
Top Cited PapersDiagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder: Synopsis of the Kidney Disease: Improving Global Outcomes 2017 Clinical Practice Guideline Update
The Kidney Disease: Improving Global Outcomes (KDIGO) 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD–MBD) is a selective update of the prior CKD–MBD guideline published in 2009. The guideline update and the original publication are intended to assist practitioners caring for adults with CKD and those receiving long-term dialysis. Development of the guideline update followed an explicit process of evidence review and appraisal. The approach adopted by the Work Group and the evidence review team was based on systematic reviews of relevant trials, appraisal of the quality of the evidence, and rating of the strength of recommendations according to the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach. Searches of the English-language literature were conducted through September 2015 and were supplemented with targeted searches through February 2017. Final modification of the guidelines was informed by a public review process involving numerous stakeholders, including patients, subject matter experts, and industry and national organizations. The update process resulted in the revision of 15 recommendations. This synopsis focuses primarily on recommendations for diagnosis of and testing for CKD–MBD and treatment of CKD–MBD that emphasizes decreasing phosphate levels, maintaining calcium levels, and addressing elevated parathyroid hormone levels in adults with CKD stage G3a to G5 and those receiving dialysis. Key elements include basing treatment on trends in laboratory values rather than a single abnormal result and being cautious to avoid hypercalcemia when treating secondary hyperparathyroidism.
- Top Cited PapersOpen Access
- 1 July 2017
- Published by Elsevier in Kidney International
- Vol. 92 (1) , 26-36
Executive summary of the 2017 KDIGO Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) Guideline Update: what’s changed and why it matters
- 1 July 2017
- Published by Elsevier in Kidney International
- Vol. 92 (1) , 26-36
Top Cited PapersOpen AccessExecutive summary of the 2017 KDIGO Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) Guideline Update: what’s changed and why it matters
- 17 May 2017
- Published by Springer Nature
- p. 229-240
Phosphorus and Cardiovascular Disease
- Open Access
- 21 April 2017
- Published by Springer Nature in Der Nephrologe
- Vol. 12 (3) , 152-153
Knochen- und Mineralstoffwechselstörungen bei Nierenkranken
- 21 April 2017
- Published by Springer Nature in Der Nephrologe
- Vol. 12 (3) , 152-153
Open AccessKnochen- und Mineralstoffwechselstörungen bei Nierenkranken
- 3 April 2017
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 28 (6) , 1667-1668
K-alcification Protection in Dialysis Patients: The Underestimated Phenomenon of Vitamin K Deficiency
- 3 April 2017
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 28 (6) , 1667-1668
K-alcification Protection in Dialysis Patients: The Underestimated Phenomenon of Vitamin K Deficiency
- 1 January 2017
- Published by Georg Thieme Verlag KG in Osteologie
- Vol. 26 (03) , 147-152
Kalziphylaxie
Die Kalziphylaxie ist eine seltene, jedoch mit hoher Morbidität und Mortalität einhergehende Erkrankung, die in erster Linie Dialysepatienten und Patienten mit fortgeschrittener Nierenerkrankung betrifft. Das klinische Bild ist durch äußerst schmerzhafte und häufig nekrotisierende Ulzerationen der Haut charakterisiert, histologisch finden sich ausgeprägte Mediaverkalkungen kutaner Arteriolen, teilweise auch Kalzifikationen im umgebenden Weichteilund Fettgewebe. Eine differenzialdiagnostische Abgrenzung zu kutanen Vaskulitiden, zur Pyoderma gangraenosum oder zu diabetischen Ulzera kann mitunter schwierig sein. In der Vergangenheit bestand die Vermutung, dass die Kalziphylaxie im Rahmen einer renalen High-turnoverOsteopathie bei unkontrolliertem Hyperparathyreoidismus kausal ausgelöst wird. Hier weisen neue Registerdaten jedoch in eine andere Richtung: Eine adyname (Low-turnover-)Osteopathie, Entzündungsprozesse, Hyperphosphatämie, Verkalkungsinhibitormangel und Vitamin-K-Antagonismus scheinen als Risikofaktoren eine dominierendere Rolle zu spielen. Therapeutische Erfolge sind mit Kalzimimetika, Bisphosphonaten und Natrium-Thiosulfat berichtet worden, allerdings nur in Fallberichten bzw. Fallserien - randomisierte Behandlungsstudien zu diesem seltenen Krankheitsbild liegen nicht vor. Potenziell vielversprechend ist die Vitamin-K-Supplementation, essenziell ist eine professionelle Wundbehandlung. Calciphylaxis is a rare disease associated with significant morbidity and mortality predominantly affecting patients with advanced chronic kidney disease and especially patients on dialysis. The clinical picture is characterized by severely painful, necrotizing skin ulcerations. In biopsy samples, circumferential media calcifications of small cutaneous arterioles are found, in some cases also calcifications of fat and soft tissues. In the differential diagnosis, vasculitis, pyoderma gangraenosum or diabetic ulcers may have to be considered. In the past, calciphylaxis was thought to be quite strictly related to high bone turnover disease in the context of uncontrolled hyperparathyroidism. New data from registries however point to other directions: Adynamic (low turnover) bone disease, inflammatory processes, hyperphosphatemia, deficiencies in calcification inhibitors and vitamin K antagonism seem to be more prominent risk factors. Therapeutic successes with calcimimetics, bisphosphonates and sodium thiosulfate have been reported, but such observations were limited to case reports or case series. Up to date, no randomized controlled trials have been reported in patients with calciphylaxis. Potentially promising is vitamin K supplementation, adequate and professional wound management is essential.
- 1 January 2017
- Published by Georg Thieme Verlag KG in Osteologie
- Vol. 26 (03) , 147-152
Kalziphylaxie
Die Kalziphylaxie ist eine seltene, jedoch mit hoher Morbidität und Mortalität einhergehende Erkrankung, die in erster Linie Dialysepatienten und Patienten mit fortgeschrittener Nierenerkrankung betrifft. Das klinische Bild ist durch äußerst schmerzhafte und häufig nekrotisierende Ulzerationen der Haut charakterisiert, histologisch finden sich ausgeprägte Mediaverkalkungen kutaner Arteriolen, teilweise auch Kalzifikationen im umgebenden Weichteilund Fettgewebe. Eine differenzialdiagnostische Abgrenzung zu kutanen Vaskulitiden, zur Pyoderma gangraenosum oder zu diabetischen Ulzera kann mitunter schwierig sein. In der Vergangenheit bestand die Vermutung, dass die Kalziphylaxie im Rahmen einer renalen High-turnoverOsteopathie bei unkontrolliertem Hyperparathyreoidismus kausal ausgelöst wird. Hier weisen neue Registerdaten jedoch in eine andere Richtung: Eine adyname (Low-turnover-)Osteopathie, Entzündungsprozesse, Hyperphosphatämie, Verkalkungsinhibitormangel und Vitamin-K-Antagonismus scheinen als Risikofaktoren eine dominierendere Rolle zu spielen. Therapeutische Erfolge sind mit Kalzimimetika, Bisphosphonaten und Natrium-Thiosulfat berichtet worden, allerdings nur in Fallberichten bzw. Fallserien - randomisierte Behandlungsstudien zu diesem seltenen Krankheitsbild liegen nicht vor. Potenziell vielversprechend ist die Vitamin-K-Supplementation, essenziell ist eine professionelle Wundbehandlung. Calciphylaxis is a rare disease associated with significant morbidity and mortality predominantly affecting patients with advanced chronic kidney disease and especially patients on dialysis. The clinical picture is characterized by severely painful, necrotizing skin ulcerations. In biopsy samples, circumferential media calcifications of small cutaneous arterioles are found, in some cases also calcifications of fat and soft tissues. In the differential diagnosis, vasculitis, pyoderma gangraenosum or diabetic ulcers may have to be considered. In the past, calciphylaxis was thought to be quite strictly related to high bone turnover disease in the context of uncontrolled hyperparathyroidism. New data from registries however point to other directions: Adynamic (low turnover) bone disease, inflammatory processes, hyperphosphatemia, deficiencies in calcification inhibitors and vitamin K antagonism seem to be more prominent risk factors. Therapeutic successes with calcimimetics, bisphosphonates and sodium thiosulfate have been reported, but such observations were limited to case reports or case series. Up to date, no randomized controlled trials have been reported in patients with calciphylaxis. Potentially promising is vitamin K supplementation, adequate and professional wound management is essential.